Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $6.22 USD
Change Today +0.13 / 2.13%
Volume 359.4K
OSUR On Other Exchanges
As of 5:20 PM 11/25/15 All times are local (Market data is delayed by at least 15 minutes).

orasure technologies inc (OSUR) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/22/14 - $10.93
52 Week Low
09/30/15 - $4.39
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

orasure technologies inc (OSUR) Related Businessweek News

No Related Businessweek News Found

orasure technologies inc (OSUR) Details

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests that are used on other specimen types. Its primary products include OraQuick ADVANCE HIV-1/2, OraQuick In-Home HIV Test, OraQuick HCV, OraSure QuickFlu rapid flu A&B test, OraSure, Oragene DX, Oragene DNA, Oragene RNA, ORAcollect, OMNIgene DISCOVER, Performagene LIVESTOCK and Oragene ANIMAL, HEMAgen BUFFY COAT, PrepIT—MAX, OMNIgene—Gut, OMNIgene Sputum, Intercept, MICRO-PLATE DOA Assays, Intercept i2, Homogeneous DOA Assays, and professional and over-the-counter Cryosurgical Systems. In addition, the company manufactures and sells oral fluid collection devices used to collect, stabilize, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic testing, academic research, pharmacogenomics, personalized medicine, and animal genetics markets. Further, it provides medical devices used for the removal of benign skin lesions by cryosurgery or freezing; various immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot HIV-1 confirmatory test for confirming positive HIV-1 test; and Q.E.D. rapid point-of-care saliva alcohol test. The company sells its products to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, research and academic institutions, distributors, government agencies, physicians’ offices, and commercial and industrial entities. OraSure Technologies, Inc. was founded in 1979 and is based in Bethlehem, Pennsylvania.

320 Employees
Last Reported Date: 03/12/15
Founded in 1979

orasure technologies inc (OSUR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $580.1K
Chief Operating Officer, Chief Financial Offi...
Total Annual Compensation: $455.7K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $327.6K
Principal Accounting Officer, Senior Vice Pre...
Total Annual Compensation: $261.8K
Executive Vice President of Marketing & Sales
Total Annual Compensation: $375.8K
Compensation as of Fiscal Year 2014.

orasure technologies inc (OSUR) Key Developments

OraSure Technologies, Inc. Reports Unaudited Consolidated Earnings Result for the Third Quarter and Nine Months Ended September 30, 2015; Provides Earnings Guidance for the Fourth Quarter of 2015

OraSure Technologies, Inc. reported unaudited consolidated earnings result for the third quarter and nine months ended September 30, 2015. The company reported third quarter diluted EPS of $0.03 per share, up a penny from a year earlier. Revenues rose 7% year-on-year to $29.9 million. Consolidated net income was $1.5 million compared to consolidated net income of $1.1 million for the third quarter of 2014. Operating income was $1.536 million compared to $0.882 million a year ago. Income before income taxes was $1.617 million compared to $1.15 million a year ago. Cash generated by operating activities in the third quarter of 2015 was $18.5 million compared to $18.8 million generated in the third quarter last year. Consolidated net revenues for the nine months ended September 30, 2015 were $87.3 million, a 12% increase from the comparable period of 2014. Consolidated net income was $3.6 million, or $0.06 per share on a fully-diluted basis, which compares to a consolidated net loss of $2.0 million, or $0.04 per share, for the comparable period of 2014. Operating income was $3.966 million compared to operating loss of $2.239 million a year ago. Income before income taxes was $4.361 million compared to loss before income taxes of $1.995 million a year ago. Capital expenditures were $1.885 million compared to $2.353 million a year ago. Cash provided by operating activities was $15.105 million compared to $8.384 million a year ago. For the fourth quarter of 2015, the company expects consolidated net revenues to range from $29.5 to $30.0 million and is projecting a consolidated net income of between $0.03 and $0.04 per share.

OraSure Technologies, Inc. Presents at Canaccord Genuity 2015 Medical Technology & Diagnostics Forum, Nov-19-2015 11:30 AM

OraSure Technologies, Inc. Presents at Canaccord Genuity 2015 Medical Technology & Diagnostics Forum, Nov-19-2015 11:30 AM. Venue: Westin Grand Central, New York, New York, United States. Speakers: Douglas A. Michels, Chief Executive Officer, President and Director.

OraSure Technologies, Inc. to Report Q3, 2015 Results on Nov 04, 2015

OraSure Technologies, Inc. announced that they will report Q3, 2015 results at 4:00 PM, US Eastern Standard Time on Nov 04, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OSUR:US $6.22 USD +0.13

OSUR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Chembio Diagnostics Inc $5.29 USD -0.035
Nymox Pharmaceutical Corp $3.25 USD -0.04
Pernix Therapeutics Holdings Inc $3.01 USD +0.01
Quidel Corp $20.99 USD +0.15
Trinity Biotech PLC $12.11 USD +0.36
View Industry Companies

Industry Analysis


Industry Average

Valuation OSUR Industry Range
Price/Earnings 100.0x
Price/Sales 3.0x
Price/Book 2.2x
Price/Cash Flow 391.4x
TEV/Sales 2.1x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ORASURE TECHNOLOGIES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at